Key points
- Ipilimumab (Yervoy) is an immunotherapy drug that makes immune cells more active against cancer [1].
- It is used for melanoma (alone or with nivolumab) and, only together with nivolumab, for kidney, bowel, liver, lung and oesophageal cancer [1].
- It is given as a 30-minute drip, usually every 3 weeks for up to 4 doses [1].
- The main risk is immune-related inflammation, especially of the bowel (diarrhoea), liver and glands; report any new symptom early [1] (immunotherapy side effects).
- Liver, kidney, thyroid and hormone tests are done before starting and before each dose [1].
- Women should avoid pregnancy during treatment and for 3 months after the last dose, and should not breastfeed [1].
What is this drug and how does it work?
For physicians
Ipilimumab (brand name Yervoy) is a human IgG1 monoclonal antibody that blocks CTLA-4 [1]. It is an immune checkpoint inhibitor and, instead of attacking cancer cells directly, works by releasing the brake on the immune system [1].
CTLA-4 is a negative regulator of T-cell activity. Ipilimumab binds CTLA-4 and blocks its interaction with its ligands (CD80 and CD86) [1]. This increases the activation and proliferation of T cells, including tumour-infiltrating effector T cells, and may also reduce regulatory T-cell function; the result is an overall increase in T-cell responsiveness and the antitumour response [1].
CTLA-4 and PD-1 are two distinct immune inhibitory pathways; according to the nivolumab label, combined blockade with nivolumab (a PD-1 inhibitor) and ipilimumab enhances T-cell function more than either drug alone [2]. Except in melanoma, ipilimumab is approved only with nivolumab [1]. This immune enhancement is also the main reason for the drug's side effects [1].
Which cancers is it used for?
According to the FDA label, ipilimumab is approved in melanoma alone or with nivolumab, and in other cancers only with nivolumab (and in lung cancer sometimes with chemotherapy) [1]. In metastatic lung cancer and oesophageal cancer, PD-L1 expression, and in colorectal cancer, MSI-H/dMMR status, play a role in patient selection [1]. Approved uses may differ between countries, and not every patient is a candidate for this drug.
Your doctor may prescribe this drug for:
- Melanoma [1, 3, 4, 5]
- Kidney cancer (renal cell carcinoma) [1, 6]
- MSI-H or dMMR colorectal cancer [1, 7]
- Hepatocellular carcinoma [1, 8]
- Non-small cell lung cancer [1, 9]
- Malignant pleural mesothelioma [1, 10]
- Oesophageal cancer (squamous cell carcinoma) [1, 11]
Whether it suits you depends on the type and stage of your cancer and your test results. Details of each use are in the section for doctors.
For physicians
| Cancer | Conditions of use | Key evidence |
|---|---|---|
| Melanoma | Unresectable or metastatic melanoma, alone or with nivolumab, in adults and children aged 12 and over; adjuvant treatment (alone) in adults with cutaneous melanoma with regional lymph node involvement of more than 1 mm after complete resection and complete lymphadenectomy [1] | MDX010-20 [3]; E1609 [4]; CheckMate 067 [5] |
| Kidney cancer (renal cell carcinoma) | First line for intermediate- or poor-risk advanced disease, with nivolumab [1] | CheckMate 214 trial [6] |
| MSI-H or dMMR colorectal cancer | Unresectable or metastatic disease, with nivolumab, in adults and children aged 12 and over [1] | CheckMate 8HW trial [7] |
| Hepatocellular carcinoma | Unresectable or metastatic disease with nivolumab, first line or after prior sorafenib [1] | CheckMate 9DW trial [8] |
| Non-small cell lung cancer | First line for metastatic disease with PD-L1 ≥1% and no EGFR or ALK alterations, with nivolumab; or first line for metastatic or recurrent disease without EGFR or ALK alterations, with nivolumab and 2 cycles of platinum doublet chemotherapy [1] | CheckMate 227 trial [9] |
| Malignant pleural mesothelioma | First line for unresectable disease, with nivolumab [1] | CheckMate 743 trial [10] |
| Oesophageal cancer (squamous cell carcinoma) | First line for advanced unresectable or metastatic disease with PD-L1 ≥1, with nivolumab [1] | CheckMate 648 trial [11] |
A summary of the FDA label; the full label has the details of each use. Neoadjuvant ipilimumab and nivolumab in resectable stage III melanoma was studied in the NADINA trial [12], but this use is not among the approved indications in the current FDA label [1].
How it is taken and dosing
Show detailsHide
Treatment regimens and doses: index10 regimens
Ipilimumab is given at a treatment centre as an intravenous drip over about 30 minutes [1]. When it is given with nivolumab, nivolumab is given first on the same day and then ipilimumab; if chemotherapy is also part of the treatment, it is given after these two [1].
Treatment schedule: in advanced melanoma (alone or with nivolumab) and in kidney, bowel and liver cancer, ipilimumab is usually given every 3 weeks for up to 4 doses, after which nivolumab continues on its own [1]. In lung cancer, mesothelioma and oesophageal cancer, ipilimumab is given every 6 weeks with nivolumab for up to 2 years [1]. In adjuvant treatment of melanoma, 4 doses are given every 3 weeks and then every 12 weeks for up to 4 more doses [1].
Tests: liver enzymes, creatinine, ACTH and thyroid function are checked before starting and before each dose [1]. If you miss an appointment, contact your treatment team as soon as possible to arrange a new one [1].
- Patient selection: PD-L1 in NSCLC and ESCC, and MSI-H/dMMR in colorectal cancer [1].
- Administration: dilute in 0.9% saline or 5% dextrose (1 to 2 mg/mL), infuse over 30 minutes with a low protein-binding in-line filter, through a separate line, and flush the line after each dose [1]. Premedication is not routinely given in the label; grade 1 to 2 infusion reaction: interrupt or slow the rate; grade 3 to 4: discontinue permanently [1].
- Dose modification: no dose reductions are recommended; with nivolumab, both drugs are withheld or discontinued together. Discontinue permanently: grade 4 immune-related adverse reaction; recurrent grade 3 requiring immunosuppression; grade 2 or 3 persisting 12 weeks or more after the last dose (except endocrine); inability to taper prednisone to 10 mg/day within 12 weeks. Grade 2 colitis: withhold; grade 3 to 4: discontinue permanently. Hepatitis without liver involvement (or non-HCC): ALT/AST above 3 to 5 times ULN or bilirubin above 1.5 to 3 times: withhold; ALT/AST above 5 times or bilirubin above 3 times: discontinue permanently. Grade 2 pneumonitis: withhold; grade 3 to 4: discontinue. Nephritis (grade 2 to 3 creatinine): withhold; grade 4: discontinue. Grade 2 neurological toxicity: withhold; grade 3 to 4: discontinue. Grade 2 to 4 myocarditis: discontinue permanently. Grade 2 to 4 ocular adverse reaction not improving to grade 1 within 2 weeks of topical treatment or requiring systemic treatment: discontinue permanently [1].
- Kidney and liver: renal impairment (GFR 15 mL/min/1.73 m² or more) and mild hepatic impairment have no important effect on clearance; the label gives no dose adjustment [1].
- Monitoring: liver tests, creatinine, ACTH and thyroid function before starting and before each dose; symptoms of colitis (diarrhoea, blood in the stool), hypophysitis and adrenal insufficiency, pneumonitis and severe rash. Immune-related adverse reactions can occur after treatment ends [1].
For physicians
Standard dosing in melanoma (FDA label, revised 08/2026)
Unresectable or metastatic melanoma, monotherapy
Adults and children aged 12 and overCycle length: 21 days
Adults and children aged 12 and over [1]
Before prescribing: Prescribing notes: patient selection, administration, dose modification and monitoring| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Up to 4 doses | |||
| Ipilimumab | 3 mg/kg | IV, 30-minute infusion | Every 3 weeks |
Unresectable or metastatic melanoma, with nivolumab
Adults and children aged 12 and over
Adults and children aged 12 and over [1]
Before prescribing: Prescribing notes: patient selection, administration, dose modification and monitoring| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Combination: 4 doses | |||
| Nivolumab | 1 mg/kg | IV, 30-minute infusion | Day 1 every 3 weeks (given first) |
| Ipilimumab | 3 mg/kg | IV, 30-minute infusion | Same day, straight after nivolumab |
| Maintenance | |||
| Nivolumab | 240 mg every 2 weeks or 480 mg every 4 weeks | IV, 30-minute infusion | Starting after the 4 combination doses |
Children under 40 kg in the maintenance phase: nivolumab 3 mg/kg every 2 weeks or 6 mg/kg every 4 weeks [2].
Melanoma, adjuvant (monotherapy)
Cutaneous melanoma with regional node involvement of more than 1 mm after complete resection and complete lymphadenectomy
Cutaneous melanoma with regional node involvement of more than 1 mm after complete resection and complete lymphadenectomy [1]
Before prescribing: Prescribing notes: patient selection, administration, dose modification and monitoring| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Induction: 4 doses | |||
| Ipilimumab | 3 mg/kg | IV, 30-minute infusion | Every 3 weeks |
| Maintenance: up to 4 doses | |||
| Ipilimumab | 3 mg/kg | IV, 30-minute infusion | Every 12 weeks |
Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.
Other cancers, with nivolumab (FDA label, revised 08/2026)
Advanced intermediate- or poor-risk renal cell carcinoma (CheckMate 214)
First line
First line [1]
Before prescribing: Prescribing notes: patient selection, administration, dose modification and monitoring| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Combination: 4 doses | |||
| Nivolumab | 3 mg/kg | IV, 30-minute infusion | Day 1 every 3 weeks (given first) |
| Ipilimumab | 1 mg/kg | IV, 30-minute infusion | Same day, after nivolumab |
| Maintenance | |||
| Nivolumab | 240 mg every 2 weeks or 480 mg every 4 weeks | IV, 30-minute infusion | After the 4 combination doses |
Evidence: CheckMate 214 (2026), CheckMate 214 (2018)
Unresectable or metastatic MSI-H/dMMR colorectal cancer (CheckMate 8HW)
Adults and children aged 12 and over; MSI-H/dMMR by an approved test
Adults and children aged 12 and over; MSI-H/dMMR by an approved test [1]
Before prescribing: Prescribing notes: patient selection, administration, dose modification and monitoring| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Combination: up to 4 doses | |||
| Nivolumab | 240 mg (below 40 kg: 3 mg/kg) | IV, 30-minute infusion | Day 1 every 3 weeks (given first) |
| Ipilimumab | 1 mg/kg | IV, 30-minute infusion | Same day, after nivolumab |
| Maintenance | |||
| Nivolumab | 240 mg every 2 weeks or 480 mg every 4 weeks (below 40 kg: 3 mg/kg every 2 weeks or 6 mg/kg every 4 weeks) | IV, 30-minute infusion | After the combination doses |
Evidence: CheckMate 8HW (2025), CheckMate 8HW (2024)
Unresectable or metastatic hepatocellular carcinoma (CheckMate 9DW)
First line or after sorafenib
First line or after sorafenib [1]
Before prescribing: Prescribing notes: patient selection, administration, dose modification and monitoring| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Combination: up to 4 doses | |||
| Nivolumab | 1 mg/kg | IV, 30-minute infusion | Day 1 every 3 weeks (given first) |
| Ipilimumab | 3 mg/kg | IV, 30-minute infusion | Same day, straight after nivolumab |
| Maintenance | |||
| Nivolumab | 240 mg every 2 weeks or 480 mg every 4 weeks | IV, 30-minute infusion | After the combination doses |
Evidence: CheckMate 9DW (2025)
Metastatic NSCLC with PD-L1 1% or more (CheckMate 227)
First line, without EGFR or ALK alterationsEach drug’s schedule in the table
First line, without EGFR or ALK alterations [1]
Before prescribing: Prescribing notes: patient selection, administration, dose modification and monitoring| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Continuous | |||
| Nivolumab | 360 mg | IV, 30-minute infusion | Every 3 weeks |
| Ipilimumab | 1 mg/kg | IV, 30-minute infusion | Every 6 weeks |
Evidence: CheckMate 227 (2019)
Metastatic or recurrent NSCLC, with 2 cycles of chemotherapy (CheckMate 9LA)
First line, without EGFR or ALK alterationsEach drug’s schedule in the table
First line, without EGFR or ALK alterations [1]
Before prescribing: Prescribing notes: patient selection, administration, dose modification and monitoring| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Continuous | |||
| Nivolumab | 360 mg | IV, 30-minute infusion | Every 3 weeks |
| Ipilimumab | 1 mg/kg | IV, 30-minute infusion | Every 6 weeks |
| First 2 cycles | |||
| Histology-based platinum doublet chemotherapy | As per those drugs' labels | IV | Every 3 weeks, after nivolumab and ipilimumab |
Unresectable malignant pleural mesothelioma (CheckMate 743)
First lineEach drug’s schedule in the table
First line [1]
Before prescribing: Prescribing notes: patient selection, administration, dose modification and monitoring| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Continuous | |||
| Nivolumab | 360 mg | IV, 30-minute infusion | Every 3 weeks |
| Ipilimumab | 1 mg/kg | IV, 30-minute infusion | Every 6 weeks |
Evidence: CheckMate 743 (2021)
Oesophageal squamous cell carcinoma with PD-L1 1 or more (CheckMate 648)
First line, advanced unresectable or metastatic
First line, advanced unresectable or metastatic [1]
Before prescribing: Prescribing notes: patient selection, administration, dose modification and monitoring| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Continuous | |||
| Nivolumab | 3 mg/kg every 2 weeks or 360 mg every 3 weeks | IV, 30-minute infusion | Day 1 |
| Ipilimumab | 1 mg/kg | IV, 30-minute infusion | Every 6 weeks |
Evidence: CheckMate 648 (2026), CheckMate 648 (2022)
Before prescribing, check each dose against the drug label, laboratory tests and the patient’s condition.
Side effects
The most common side effects:
- Tiredness, diarrhoea, itching and skin rash, nausea and headache [1].
- Side effects are more common when it is given with nivolumab: muscle and joint pain, fever, cough, poor appetite, abdominal pain and an underactive thyroid [1].
- Report any new or worsening symptom early; it may be the first sign of an immune side effect [1].
For physicians
According to the FDA label, the most common adverse reactions to ipilimumab alone (20% or more) are fatigue, diarrhoea, pruritus, rash, nausea and headache [1]. In combination with nivolumab, the list of common adverse reactions is longer and also includes musculoskeletal pain, pyrexia, cough, decreased appetite, vomiting, abdominal pain, dyspnoea, upper respiratory tract infection, arthralgia, hypothyroidism, constipation, weight loss and dizziness [1].
The table below shows the frequency of some adverse reactions in three trials: MDX010-20 (advanced melanoma, ipilimumab 3 mg/kg alone, 131 patients), E1609 (adjuvant melanoma, ipilimumab 3 mg/kg, 516 patients) and CheckMate 067 (advanced melanoma, ipilimumab with nivolumab, 313 patients) [1].
| Adverse reaction | Monotherapy, advanced melanoma (MDX010-20) | Adjuvant melanoma (E1609) | With nivolumab (CheckMate 067) |
|---|---|---|---|
| Fatigue | 41% [1] | 56% [1] | 62% [1] |
| Diarrhoea | 32% [1] | 49% [1] | 54% [1] |
| Pruritus | 31% [1] | 41% [1] | — |
| Rash | 29% [1] | 46% [1] | 53% [1] |
| Colitis | 8% [1] | 10% [1] | — |
| Nausea | — | 29% [1] | 44% [1] |
| Headache | — | 25% [1] | — |
| Pyrexia | — | 10% [1] | 40% [1] |
“—” means the reaction was not reported in that trial's table in the FDA label. Figures from different trials are not directly comparable.
Serious side effects
Ipilimumab, more than most immunotherapy drugs, can make the immune system attack healthy organs; these side effects can happen at any time, even after treatment has ended [1] (immunotherapy side effects):
- Bowel: diarrhoea, abdominal pain or blood in the stool; the most common serious side effect of this drug [1].
- Skin: a widespread rash, blisters or mouth sores [1].
- Liver: yellow skin or eyes, dark urine [1].
- Glands (thyroid, pituitary, adrenal): severe tiredness, headache, dizziness, changes in weight or mood [1].
- Lungs, kidneys, nerves, heart and eyes: cough or shortness of breath, passing less urine, weakness or numbness, palpitations, blurred vision or eye pain [1].
- Harm to an unborn baby [1].
For physicians
Ipilimumab can cause severe or fatal immune-related adverse reactions in any organ; they may appear at any time after starting treatment and even after it is stopped [1]. Frequencies depend on the dose and combination [1]:
- Ipilimumab 3 mg/kg alone (511 patients): colitis 12% (grade 3 to 5: 7%), immune-mediated rash 15%, immune-mediated hepatitis 4.1%, and grade 2 to 5 endocrinopathies in 4% [1].
- Ipilimumab 3 mg/kg with nivolumab 1 mg/kg (melanoma or HCC, 456 patients): colitis 25%, immune-mediated rash 28%, hypothyroidism 20%, hepatitis 15%, hypophysitis 9%, hyperthyroidism 9%, adrenal insufficiency 8% and pneumonitis 7% [1].
- Ipilimumab 1 mg/kg with nivolumab 3 mg/kg (RCC or CRC, 666 patients): hypothyroidism 18%, immune-mediated rash 16%, hyperthyroidism 12%, colitis 9%, hepatitis 7%, adrenal insufficiency 7%, hypophysitis 4.4%, nephritis 4.1%, pneumonitis 3.9% and diabetes 2.7% [1].
- Rarer reactions: autoimmune neuropathy (2%), pancreatitis (1.3%), meningitis, encephalitis, myasthenia gravis, Guillain-Barré syndrome, myocarditis and ocular inflammation such as uveitis [1].
- Infusion-related reactions: 0.6% with ipilimumab 3 mg/kg alone and 5% with ipilimumab 1 mg/kg with nivolumab [1].
In the adjuvant trial E1609, fatal adverse reactions occurred in 1.4% of patients receiving ipilimumab and 35% permanently stopped the drug because of an adverse reaction [1]. Severe or fatal graft-versus-host disease may occur in patients given ipilimumab before or after allogeneic stem cell transplantation [1]. Ipilimumab can harm a fetus, with effects probably greater in the second and third trimesters [1]. The current FDA label for this drug has no boxed warning [1].
When should I call my doctor?
If you have any of these new or worsening symptoms, contact your doctor or treatment team straight away, even if treatment has finished [1]:
- Diarrhoea or more frequent bowel movements, black tarry stools or stools with blood or mucus, or severe abdominal pain or tenderness [1]
- Yellow skin or whites of the eyes, severe nausea or vomiting, pain on the right side of the abdomen, dark (tea-coloured) urine, or bleeding and bruising easily [1]
- Rash, itching, blistering or peeling skin, or painful sores in the mouth, nose, throat or genital area [1]
- A persistent or unusual headache, eye sensitivity to light, palpitations, heavy sweating, extreme tiredness, weight change, excessive thirst or hunger, passing a lot of urine, dizziness or fainting [1]
- A new or worsening cough, shortness of breath or chest pain [1]
- Passing less urine, blood in the urine or swollen ankles [1]
- Blurred or double vision or other eyesight problems, eye pain or redness [1]
- During the infusion: chills, itching or rash, flushing, shortness of breath or wheezing, dizziness, feeling faint, fever, or back or neck pain [1]
In severe cases (such as severe shortness of breath, severe bloody diarrhoea or reduced consciousness), call your local emergency number.
Interactions, pregnancy and precautions
Drug interactions: the FDA label for ipilimumab has no section on drug interactions [1]; even so, tell your doctor about all your medicines, over-the-counter drugs, vitamins and herbal supplements [1]. The safety and effectiveness of ipilimumab with vemurafenib have not been established, and in a dose-finding study grade 3 liver enzyme rises occurred in 6 of 10 patients [1].
Before starting treatment, tell your doctor if you have an autoimmune disease (such as ulcerative colitis, Crohn disease or lupus), have had an organ transplant or a stem cell transplant from a donor, or have a nerve disease such as myasthenia gravis or Guillain-Barré syndrome [1].
Pregnancy and contraception: ipilimumab may harm an unborn baby. Pregnancy status is checked before starting, and women who could become pregnant should use effective contraception during treatment and for 3 months after the last dose [1].
Breastfeeding: do not breastfeed during treatment and for 3 months after the last dose [1].
Fertility: no studies have looked at the effect of ipilimumab on fertility [1]; if you are planning a family, talk to your doctor before starting treatment.
Vaccines: the FDA label gives no specific advice about vaccination [1]; talk to your treatment team before any vaccine.
Frequently asked questions
Is ipilimumab chemotherapy?
No. Ipilimumab is an immunotherapy from the immune checkpoint inhibitor group that works with the body's immune system [1].
Why is ipilimumab usually given with nivolumab?
How long does treatment last?
In most regimens ipilimumab is given for up to 4 doses (every 3 weeks), after which nivolumab continues on its own; in lung cancer, mesothelioma and oesophageal cancer for up to 2 years, and in adjuvant treatment of melanoma for up to 4 more doses every 12 weeks [1].
Is diarrhoea during treatment serious?
Can side effects start after treatment has ended?
Yes. Immune-related side effects usually appear during treatment, but they can also appear after the drug is stopped [1].
Key studies
Show detailsHide
Key studies
6 itemsFinal, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Related cancer types
Treatment regimens (physicians)
References
12 referencesShow all references, 10 with a study cardClose the reference list
Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.
- 1YERVOY (ipilimumab) injection, for intravenous use: Prescribing InformationSource Back to text: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127
- 2
- 3Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- 4Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
- 5Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
- 6Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- 7Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer
- 8Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
- 9Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- 10First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
- 11Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
- 12Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
This page is based on reputable scientific sources and was last updated on 27 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.
Printed from the website; the full and up-to-date version: https://drdabiri.com/en/drugs/ipilimumab/